Tinostamustine

About Imbrium Therapeutics

Imbrium Therapeutics is a U.S.-based, clinical-stage biotech company, wholly owned by Purdue Pharma L.P., which is undergoing a court-approved bankruptcy reorganization. The company's strategic focus is on developing first-in-class small molecule therapies for high-need areas, including glioblastoma and non-opioid pain. Its lead asset, tinostamustine, is in clinical development for glioblastoma, representing a novel dual-mechanism approach. The firm's future is contingent on the successful emergence of the restructured Knoa Pharma entity from bankruptcy, which will determine its operational and financial trajectory.

About Purdue Pharma

Purdue Pharma is a U.S.-based pharmaceutical company in the final stages of a court-approved Chapter 11 bankruptcy reorganization, set to re-emerge as Knoa Pharma. Historically known for its role in the opioid epidemic, the restructured company aims to pivot towards a future centered on a pipeline of novel therapeutics while continuing to meet obligations from its legacy business. Its current operations include developing a clinical-stage oncology asset and maintaining a stated commitment to funding opioid crisis abatement programs as part of its bankruptcy settlement.

Therapeutic Areas

Other Glioblastoma Multiforme (GBM) Drugs